Last updated on November 2017

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, 52-WEEK EFFICACY AND SAFETY STUDY OF RO5285119 IN ADULTS WITH AUTISM SPECTRUM DISORDERS (ASD) WITH A 2-YEAR OPEN LABEL EXTENSION


Brief description of study

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, 52-WEEK EFFICACY AND SAFETY STUDY OF RO5285119 IN ADULTS WITH AUTISM SPECTRUM DISORDERS (ASD) WITH A 2-YEAR OPEN LABEL EXTENSION

Detailed Study Description

Adult Autism disorder trial with an open label extension

Clinical Study Identifier: TX13063

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Jay Dobson

Northwest Clinical Research Center
Bellevue, WA USA
  Connect »